Accutane has been linked to suicide, depression, severe
birth defects, and damage to the liver, kidneys, and colon. Other side
effects include headaches, nausea, vomiting, bone and muscle problems,
blurred vision, hearing problems, dizziness, mood changes, severe
stomach pain, diarrhea, rectal bleeding, lipids or fats and cholesterol
in blood problems, allergic reactions, dryness of the eyes, yellowing
of the skin or eyes and dark urine.
Accutane may cause depression, psychosis and an
obsession on suicidal thoughts. People taking Accutane have a higher
than normal rate of suicide attempts, suicide, and aggressive or
violent behavior. Symptoms often continue after treatment has ended.
Many parents of teenagers taking Accutane have reported
serious depression and mood changes in their children while taking
Accutane. The manufacturer believes there is no evidence showing
Accutane is responsible for feelings of depression or suicidal
tendencies, but the death toll has continued to rise despite this.
Since 1982, there have been 142 suicides involving Accutane.
Accutane presents such a high risk during pregnancy
that the FDA now requires all female users to enroll in a national
registry called iPLEDGE and sign a form stating they know of the drug’s
risks. These risk include mental retardation and severe brain and heart
defects in babies. Doctors are required to perform pregnancy tests on
women before prescribing Accutane and then re-test them each month
thereafter. They also must agree to use at least two forms of birth
control while taking Accutane.
-
Brain problems:
Accutane can cause increased pressure on the brain, a condition known
as pseudotumor cerebri. Early signs and symptoms of pseudotumor cerebri
include swelling around the optic nerve, headache, nausea and vomiting,
and visual disturbances.
-
Organ and system failure: There
have been reports of internal organ damage and systems failures as a
result of using Accutane. These include damage to the colon, liver,
kidney, central nervous system, gastrointestinal tract, cardiovascular
system, skeletal system, bone density, eyes, hearing and skin.
The FDA labeling revision for the drug states in part:
"All patients treated with isotretinoin should be observed closely for
symptoms of depression or suicidal thoughts, such as sad mood,
irritability, acting on dangerous impulses, anger, loss of pleasure or
interest in social or sports activities, sleeping too much or too
little, changes in weight or appetite, school or work performance going
down, or trouble concentrating, or for mood disturbance, psychosis, or
aggression. Patients should stop isotretinoin and they or their
caregiver should contact their healthcare professional right away if
the patient has any of the previously mentioned symptoms.
Discontinuation of treatment may be insufficient and further evaluation
may be necessary."
The FDA has required that doctors and patients sign a lengthy
consent form prior to beginning Accutane therapy acknowledging they
have been informed of the dangers.